Survivorship Programs Improve Quality of Life, Satisfaction in Prostate Cancer
the Cancer Therapy Advisor take:
Men with prostate cancer managed in a survivorship program report higher quality of life (QOL) and satisfaction than those who were managed by routine care, according to an article published online in Cancer.
In this study, patient-reported outcomes (PROs) such as QOL were integrated into a prostate cancer survivorship clinic and evaluated at 6 and 12 months.
Participants included 235 men being surgically treated for prostate cancer using routine follow-up care and 102 men managed in the survivorship clinic with the integrated point-of-care QOL reporting after radical prostatectomy.
Results showed that baseline QOL was comparable, but men in the survivorship groups had higher scores at 6 and 12 months than those following the routine care. For example, male patients in the survivorship clinic reported higher sexual function than those in routine care (52.2 vs 33.6 at 1 year, P<0.05).
The study suggests that disease-specific survivorship clinics with integrated QOL reporting may generate better results than clinics with routine care following cancer therapy.
Men with prostate cancer managed in a survivorship program report higher quality of life and satisfaction.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer